Targeting a host process as an antiviral approach against dengue virus

Trends in Microbiology

Volumn 18, Issue 7, 2010, Pages 323-330

  Sayce, Andrew C ^a   Miller, Joanna L ^b   Zitzmann, Nicole ^b  

^a CLEMSON UNIVERSITY   (United States)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

1 DEOXYNOJIRIMYCIN; 1 DEOXYNOJIRIMYCIN DERIVATIVE; 7 DEAZA 2' METHYLADENOSINE; ALPHA GLUCOSIDASE; ANTIVIRUS AGENT; BUTYLCYCLOHEXYLDEOXYNOJIRIMYCIN; BUTYLDEOXYNOJIRIMYCIN; CASTANOSPERMINE; CASTANOSPERMINE 6 BUTYRATE; CM 978; MIGLUSTAT; NONYLDEOXYNOJIRIMYCIN; OSL 9511; PBDNJ 0801; PBDNJ 0803; PBDNJ 0804; PENTYL(1 HYDROXYCYCLOHEXYL)DEOXYNOJIRIMYCIN; PEPTIDE CONJUGATED PHOSPHORODIAMIDATE MORPHOLINO OLIGOMER DERIVATIVE; PHOSPHORODIAMIDATE MORPHOLINO OLIGOMER DERIVATIVE; PI 88; PLACEBO; PROPYLCYCLOHEXYLDEOXYNOJIRIMYCIN; RIBAVIRIN; SP 169; SP 173; UNCLASSIFIED DRUG; ZIDOVUDINE; ENZYME INHIBITOR; VIRUS PROTEIN;

ANTIBODY DEPENDENT ENHANCEMENT; ANTIVIRAL ACTIVITY; ANTIVIRAL THERAPY; CLINICAL TRIAL; DENGUE; DENGUE VIRUS; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG IDENTIFICATION; DRUG MEGADOSE; DRUG PROTEIN BINDING; DRUG STRUCTURE; DRUG TARGETING; GAUCHER DISEASE; HUMAN; NONHUMAN; PRIORITY JOURNAL; REVIEW; SURVIVAL RATE; SURVIVAL TIME; UNSPECIFIED SIDE EFFECT; VIREMIA; VIRION; VIRUS CELL INTERACTION; VIRUS MORPHOGENESIS; ANIMAL; BIOLOGICAL MODEL; CELL LINE; GLYCOSYLATION; HAMSTER; HOST PATHOGEN INTERACTION; IC50; METABOLISM; PATHOGENICITY; PROTEIN PROCESSING;

ANIMALS; ANTIVIRAL AGENTS; CELL LINE; CRICETINAE; DENGUE; DENGUE VIRUS; ENZYME INHIBITORS; GLYCOSYLATION; HOST-PATHOGEN INTERACTIONS; HUMANS; INHIBITORY CONCENTRATION 50; MODELS, BIOLOGICAL; PROTEIN PROCESSING, POST-TRANSLATIONAL; VIRAL PROTEINS;

DENGUE VIRUS;

EID: 77954143268     PISSN: 0966842X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tim.2010.04.003     Document Type: Review

References (65)

1. Gubler D.J., et al. Flaviviruses. Fields Virology 2006, 1153-1252. Lippincott Williams & Wilkins, Ch. 34. 5th edn. D.M. Knipe, P.M. Howley (Eds.).
2. Kuno G., et al. Phylogeny of the genus Flavivirus. J. Virol. 1998, 72:73-83.
3. Halstead S.B. Dengue. Lancet 2007, 370:1644-1652.
4. Libraty D.H., et al. High circulating levels of the dengue virus nonstructural protein NS1 early in dengue illness correlate with the development of dengue hemorrhagic fever. J. Infect. Dis. 2002, 186:1165-1168.
5. Vaughn D.W., et al. Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity. J. Infect. Dis. 2000, 181:2-9.
6. Halstead S.B. Dengue: overview and history. Dengue 2008, 1-28. Imperial College Press, Ch. 1. S.B. Halstead (Ed.).
7. Farrar J. Clinical features of dengue. Dengue 2008, 171-192. Imperial College Press, Ch. 5. S.B. Halstead (Ed.).
8. WHO The Global Burden of Disease: 2004 Update 2004, World Health Organization, pp. 53-96.
9. WHO DengueNet 2009, World Health Organization.
10. Cho Min N. Assessment of dengue hemorrhagic fever in Myanmar. Southeast Asian J. Trop. Med. Public Health 2000, 31:636-641.
11. Meltzer M.I., et al. Using disability-adjusted life years to assess the economic impact of dengue in Puerto Rico: 1984-1994. Am. J. Trop. Med. Hyg. 1998, 59:265-271.
12. Wills B. Managment of dengue. Dengue 2008, 193-218. Imperial College Press, Ch. 6. S.B. Halstead (Ed.).
13. Whitehead S.S., et al. Prospects for a dengue virus vaccine. Nat. Rev. Microbiol. 2007, 5:518-528.
14. Damonte E.B., et al. Prospects for the therapy and prevention of dengue virus infections. Adv. Virus Res. 2004, 63:239-285.
15. Li Z., et al. Design, synthesis, and biological evaluation of antiviral agents targeting flavivirus envelope proteins. J. Med. Chem. 2008, 51:4660-4671.
16. Perera R., et al. Closing the door on flaviviruses: entry as a target for antiviral drug design. Antiviral Res. 2008, 80:11-22.
17. Malet H., et al. The flavivirus polymerase as a target for drug discovery. Antiviral Res. 2008, 80:23-35.
18. Sampath A., Padmanabhan R. Molecular targets for flavivirus drug discovery. Antiviral Res. 2009, 81:6-15.
19. Yin Z., et al. An adenosine nucleoside inhibitor of dengue virus. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:20435-20439.
20. Lescar J., et al. Towards the design of antiviral inhibitors against flaviviruses: the case for the multifunctional NS3 protein from Dengue virus as a target. Antiviral Res. 2008, 80:94-101.
21. Balsitis S., et al. Lethal antibody enhancement of dengue disease in mice is prevented by Fc modification. PLoS Pathog. 2010, 6:e1000790.
22. Williams K.L., et al. A mouse model for studying dengue virus pathogenesis and immune response. Ann. N. Y. Acad. Sci. 2009, 1171(Suppl. 1):E12-23.
23. Zellweger R.M., et al. Enhanced infection of liver sinusoidal endothelial cells in a mouse model of antibody-induced severe dengue disease. Cell Host Microbe 2010, 7:128-139.
24. Pollock S., et al. Uptake and trafficking of liposomes to the endoplasmic reticulum. FASEB J. 2010, http://www.fasebj.org/, 10.1096/fj.09-145755.
25. Sessions O.M., et al. Discovery of insect and human dengue virus host factors. Nature 2009, 458:1047-1050.
26. Limjindaporn T., et al. Interaction of dengue virus envelope protein with endoplasmic reticulum-resident chaperones facilitates dengue virus production. Biochem. Biophys. Res. Commun. 2009, 379:196-200.
27. Barradas J.S., et al. Synthesis and antiviral activity of azoles obtained from carbohydrates. Carbohydr. Res. 2008, 343:2468-2474.
28. Sepúlveda C., et al. Synthesis and evaluation of N-substituted acridones as antiviral agents against haemorrhagic fever viruses. Antivir. Chem. Chemother. 2008, 19:41-47.
29. Zhang X.G., et al. Antiviral activity of geneticin against dengue virus. Antiviral Res. 2009, 83:21-27.
30. Aman M.J., et al. Development of a broad-spectrum antiviral with activity against Ebola virus. Antiviral Res. 2009, 83:245-251.
31. Datema R., et al. On the role of oligosaccharide trimming in the maturation of Sindbis and influenza virus. Arch. Virol. 1984, 81:25-39.
32. Tan A., et al. Chemical modification of the glucosidase inhibitor 1-deoxynojirimycin. Structure-activity relationships. J. Biol. Chem. 1991, 266:14504-14510.
33. Durantel D., et al. Study of the mechanism of antiviral action of iminosugar derivatives against bovine viral diarrhea virus. J. Virol. 2001, 75:8987-8998.
34. Alonzi D.S., et al. Glucosylated free oligosaccharides are biomarkers of endoplasmic reticulum alpha-glucosidase inhibition. Biochem. J. 2008, 409:571-580.
35. Pavlovic D., et al. The hepatitis C virus p7 protein forms an ion channel that is inhibited by long-alkyl-chain iminosugar derivatives. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:6104-6108.
36. Steinmann E., et al. Antiviral effects of amantadine and iminosugar derivatives against hepatitis C virus. Hepatology 2007, 46:330-338.
37. Zitzmann N., et al. Imino sugars inhibit the formation and secretion of bovine viral diarrhea virus, a pestivirus model of hepatitis C virus: implications for the development of broad spectrum anti-hepatitis virus agents. Proc. Natl. Acad. Sci. U. S. A. 1999, 96:11878-11882.
38. Lu X., et al. The alkylated imino sugar, n-(n-Nonyl)-deoxygalactonojirimycin, reduces the amount of hepatitis B virus nucleocapsid in tissue culture. J. Virol. 2003, 77:11933-11940.
39. Mehta A., et al. Inhibition of hepatitis B virus DNA replication by imino sugars without the inhibition of the DNA polymerase: therapeutic implications. Hepatology 2001, 33:1488-1495.
40. Chang J., et al. Novel imino sugar derivatives demonstrate potent antiviral activity against flaviviruses. Antimicrob. Agents Chemother. 2009, 53:1501-1508.
41. Gu B., et al. Antiviral profiles of novel iminocyclitol compounds against bovine viral diarrhea virus, West Nile virus, dengue virus and hepatitis B virus. Antivir. Chem. Chemother. 2007, 18:49-59.
42. Tan A., et al. Introduction of oxygen into the alkyl chain of N-decyl-dNM decreases lipophilicity and results in increased retention of glucose residues on N-linked oligosaccharides. Glycobiology 1994, 4:141-149.
43. Liang P.H., et al. Novel five-membered iminocyclitol derivatives as selective and potent glycosidase inhibitors: new structures for antivirals and osteoarthritis. Chembiochem 2006, 7:165-173.
44. Whitby K., et al. Castanospermine, a potent inhibitor of dengue virus infection in vitro and in vivo. J. Virol. 2005, 79:8698-8706.
45. Courageot M.P., et al. Alpha-glucosidase inhibitors reduce dengue virus production by affecting the initial steps of virion morphogenesis in the endoplasmic reticulum. J. Virol. 2000, 74:564-572.
46. Yauch L.E., Shresta S. Mouse models of dengue virus infection and disease. Antiviral Res. 2008, 80:87-93.
47. Schul W., et al. A dengue fever viremia model in mice shows reduction in viral replication and suppression of the inflammatory response after treatment with antiviral drugs. J. Infect. Dis. 2007, 195:665-674.
48. Malinoski F.J., et al. Prophylactic ribavirin treatment of dengue type 1 infection in rhesus monkeys. Antiviral Res. 1990, 13:139-149.
49. Durantel D. Celgosivir, an alpha-glucosidase I inhibitor for the potential treatment of HCV infection. Curr. Opin. Investig. Drugs 2009, 10:860-870.
50. Fleet G.W., et al. Inhibition of HIV replication by amino-sugar derivatives. FEBS Lett. 1988, 237:128-132.
51. Ratner L., Vander Heyden N. Mechanism of action of N-butyl deoxynojirimycin in inhibiting HIV-1 infection and activity in combination with nucleoside analogs. AIDS Res. Hum. Retroviruses 1993, 9:291-297.
52. Tierney M., et al. The tolerability and pharmacokinetics of N-butyl-deoxynojirimycin in patients with advanced HIV disease (ACTG 100). The AIDS Clinical Trials Group (ACTG) of the National Institute of Allergy and Infectious Diseases. J. Acquir. Immune. Defic. Syndr. Hum. Retrovirol. 1995, 10:549-553.
53. Fischl M.A., et al. The safety and efficacy of combination N-butyl-deoxynojirimycin (SC-48334) and zidovudine in patients with HIV-1 infection and 200-500 CD4 cells/mm3. J. Acquir. Immune. Defic. Syndr. 1994, 7:139-147.
54. Pollock S., et al. N-Butyldeoxynojirimycin is a broadly effective anti-HIV therapy significantly enhanced by targeted liposome delivery. AIDS 2008, 22:1961-1969.
55. Murray C.L., et al. Architects of assembly: roles of Flaviviridae non-structural proteins in virion morphogenesis. Nat. Rev. Microbiol. 2008, 6:699-708.
56. Rawlings A.J., et al. Synthesis and biological characterisation of novel N-alkyl-deoxynojirimycin alpha-glucosidase inhibitors. Chembiochem 2009, 10:1101-1105.
57. Wu S.F., et al. Antiviral effects of an iminosugar derivative on flavivirus infections. J. Virol. 2002, 76:3596-3604.
58. Crabtree M.B., et al. Deglycosylation of the NS1 protein of dengue 2 virus, strain 16681: construction and characterization of mutant viruses. Arch. Virol. 2005, 150:771-786.
59. Mackenzie J.M., et al. Immunolocalization of the dengue virus nonstructural glycoprotein NS1 suggests a role in viral RNA replication. Virology 1996, 220:232-240.
60. Muylaert I.R., et al. Mutagenesis of the N-linked glycosylation sites of the yellow fever virus NS1 protein: effects on virus replication and mouse neurovirulence. Virology 1996, 222:159-168.
61. Tajima S., et al. Characterization of Asn130-to-Ala mutant of dengue type 1 virus NS1 protein. Virus Genes 2008, 36:323-329.
62. Winkler G., et al. Newly synthesized dengue-2 virus nonstructural protein NS1 is a soluble protein but becomes partially hydrophobic and membrane-associated after dimerization. Virology 1989, 171:302-305.
63. Stein D.A., et al. Treatment of AG129 mice with antisense morpholino oligomers increases survival time following challenge with dengue 2 virus. J. Antimicrob. Chemother. 2008, 62:555-565.
64. Lee E., et al. Antiviral effect of the heparan sulfate mimetic, PI-88, against dengue and encephalitic flaviviruses. Antiviral Res. 2006, 69:31-38.
65. Ruddock L.W., Molinari M. N-glycan processing in ER quality control. J. Cell Sci. 2006, 119:4373-4380.